We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Isofol Medical AB (ISOFOL) NPV

Sell:0.75 SEK Buy:0.77 SEK Change: 0.014 SEK (1.85%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:0.75 SEK
Buy:0.77 SEK
Change: 0.014 SEK (1.85%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:0.75 SEK
Buy:0.77 SEK
Change: 0.014 SEK (1.85%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.

Contact details

Address:
Biotech Center, Arvid Wallgrens Backe 20
GOETEBORG
413 46
Sweden
Telephone:
+46 (31) 7972280
Website:
https://isofolmedical.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ISOFOL
ISIN:
SE0009581051
Market cap:
124.69 million SEK
Shares in issue:
161.52 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Unclassified
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Petter Lindqvist
    Chief Executive Officer
  • Magnus Hurst
    Chief Financial Officer
  • Jenny Sundqvist
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.